Stocks Overview

LAST PRICE
24.9000
TODAY'S CHANGE (%)
Trending Up0.0500 (0.2012%)

Bid / Lots
24.7000/ 1
Ask / Lots
26.0000/ 2
Open / Previous Close
24.7000 / 24.8500
Day Range
Low 24.5300
High 24.9150
52 Week Range
Low 24.5300
High 42.7200
Volume
750,153
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Monday's close: 24.87
Time	Volume	GMAB
09:32 ET	14079	24.69
09:34 ET	310	24.69
09:36 ET	10458	24.7
09:38 ET	1200	24.74
09:39 ET	1059	24.75
09:41 ET	5843	24.73
09:43 ET	265	24.75
09:45 ET	2209	24.73
09:48 ET	525	24.72
09:50 ET	900	24.72
09:52 ET	1375	24.704
09:54 ET	500	24.67
09:56 ET	1826	24.69
09:57 ET	1000	24.69
09:59 ET	1300	24.67
10:01 ET	4937	24.61
10:03 ET	700	24.62
10:06 ET	1524	24.55
10:08 ET	1178	24.55
10:10 ET	3028	24.5465
10:12 ET	3243	24.54
10:14 ET	821	24.54
10:15 ET	700	24.54
10:17 ET	3918	24.59
10:19 ET	1429	24.6
10:21 ET	1350	24.6
10:24 ET	338	24.63
10:26 ET	100	24.63
10:28 ET	332	24.63
10:30 ET	923	24.67
10:32 ET	3194	24.71
10:33 ET	504	24.7
10:37 ET	708	24.74
10:39 ET	1220	24.73
10:42 ET	1250	24.69
10:44 ET	1230	24.7
10:46 ET	100	24.69
10:48 ET	700	24.69
10:50 ET	1187	24.69
10:51 ET	5036	24.68
10:53 ET	1541	24.72
10:55 ET	1100	24.745
10:57 ET	500	24.75
11:00 ET	6314	24.78
11:02 ET	2335	24.81
11:04 ET	567	24.81
11:06 ET	5427	24.86
11:08 ET	2020	24.89
11:09 ET	3108	24.89
11:11 ET	755	24.86
11:13 ET	564	24.85
11:15 ET	18164	24.88
11:18 ET	717	24.88
11:20 ET	412	24.88
11:22 ET	14842	24.825
11:24 ET	4455	24.78
11:26 ET	2280	24.79
11:27 ET	1646	24.84
11:29 ET	738	24.85
11:31 ET	700	24.87
11:33 ET	1320	24.84
11:36 ET	682	24.82
11:38 ET	1011	24.81
11:40 ET	400	24.8
11:42 ET	200	24.805
11:44 ET	5554	24.83
11:45 ET	22169	24.85
11:47 ET	1321	24.84
11:49 ET	10925	24.85
11:51 ET	1998	24.81
11:54 ET	1330	24.84
11:56 ET	100	24.84
11:58 ET	1022	24.8484
12:00 ET	1552	24.87
12:02 ET	1897	24.87
12:03 ET	200	24.865
12:05 ET	900	24.86
12:07 ET	200	24.865
12:09 ET	400	24.865
12:12 ET	842	24.85
12:14 ET	620	24.86
12:16 ET	600	24.87
12:18 ET	600	24.87
12:20 ET	200	24.87
12:21 ET	700	24.87
12:23 ET	3205	24.856
12:25 ET	217	24.86
12:27 ET	2847	24.845
12:30 ET	340	24.85
12:32 ET	500	24.865
12:34 ET	2878	24.85
12:36 ET	500	24.8699
12:38 ET	2122	24.86
12:39 ET	828	24.845
12:41 ET	200	24.83
12:43 ET	4549	24.82
12:45 ET	100	24.82
12:48 ET	300	24.815
12:50 ET	1059	24.825
12:52 ET	314	24.8292
12:54 ET	100	24.825
12:56 ET	951	24.82
12:57 ET	1450	24.82
12:59 ET	4718	24.795
01:01 ET	880	24.795
01:03 ET	350	24.785
01:08 ET	1356	24.795
01:10 ET	1073	24.8
01:12 ET	400	24.81
01:14 ET	2604	24.83
01:15 ET	1678	24.84
01:17 ET	2422	24.835
01:19 ET	200	24.83
01:21 ET	800	24.825
01:24 ET	1100	24.79
01:26 ET	400	24.785
01:28 ET	1238	24.79
01:30 ET	800	24.78
01:32 ET	804	24.78
01:33 ET	3977	24.7575
01:37 ET	1944	24.775
01:39 ET	431	24.785
01:42 ET	900	24.8
01:44 ET	12746	24.83
01:46 ET	26766	24.795
01:48 ET	4000	24.77
01:50 ET	2630	24.76
01:51 ET	4960	24.78
01:53 ET	100	24.79
01:55 ET	2871	24.82
01:57 ET	3053	24.83
02:00 ET	450	24.82
02:02 ET	200	24.83
02:04 ET	1733	24.8102
02:06 ET	2300	24.81
02:08 ET	675	24.81
02:09 ET	1610	24.82
02:11 ET	487	24.8101
02:13 ET	1400	24.815
02:15 ET	1370	24.83
02:18 ET	1065	24.84
02:20 ET	883	24.83
02:22 ET	844	24.84
02:24 ET	300	24.84
02:26 ET	800	24.835
02:27 ET	701	24.835
02:29 ET	2551	24.835
02:31 ET	196	24.84
02:33 ET	200	24.835
02:36 ET	2195	24.83
02:38 ET	278	24.835
02:40 ET	856	24.835
02:42 ET	1870	24.835
02:44 ET	3782	24.85
02:45 ET	224	24.855
02:47 ET	1150	24.85
02:49 ET	1011	24.84
02:51 ET	1083	24.83
02:54 ET	1602	24.83
02:56 ET	729	24.825
02:58 ET	780	24.835
03:00 ET	300	24.835
03:02 ET	2985	24.83
03:03 ET	850	24.83
03:05 ET	550	24.84
03:07 ET	702	24.84
03:09 ET	1016	24.84
03:12 ET	8025	24.84
03:14 ET	800	24.8359
03:16 ET	418	24.845
03:18 ET	490	24.85
03:20 ET	2082	24.86
03:21 ET	6130	24.88
03:23 ET	7832	24.89
03:25 ET	4692	24.895
03:27 ET	9512	24.89
03:30 ET	2240	24.895
03:32 ET	1465	24.895
03:34 ET	3413	24.895
03:36 ET	693	24.895
03:38 ET	16342	24.89
03:39 ET	5356	24.89
03:41 ET	6865	24.895
03:43 ET	5373	24.9
03:45 ET	14820	24.905
03:48 ET	2666	24.905
03:50 ET	1432	24.905
03:52 ET	4080	24.89
03:54 ET	5036	24.895
03:56 ET	14915	24.89
03:57 ET	14781	24.905
03:59 ET	20468	24.9

Data delayed at least 15 minutes.

Jun 28, 2024
- Epcoritamab (TEPKINLY(R) ) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma, from 2:00AM ET on Friday Jun 28, 2024 by Dow Jones
  2:00AM ET on Friday Jun 28, 2024 by Dow Jones
- Epcoritamab (TEPKINLY(R)) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma, from 2:00AM ET on Friday Jun 28, 2024 by Dow Jones
  2:00AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
- DJ Genmab Is Maintained at Buy by BTIG, from 8:11AM ET on Thursday Jun 27, 2024 by Dow Jones
  8:11AM ET on Thursday Jun 27, 2024 by Dow Jones
- DJ Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 6:41AM ET on Thursday Jun 27, 2024 by Dow Jones
  6:41AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 26, 2024
- DJ AbbVie Gets New FDA Accelerated Approval for Epkinly, from 7:35PM ET on Wednesday Jun 26, 2024 by Dow Jones
  7:35PM ET on Wednesday Jun 26, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesGMAB Genmab A/S	16.5B	20.9x	+22.71%
United StatesGLPG Galapagos NV	1.7B	50.6x	---
United StatesBEAM Beam Therapeutics Inc	1.9B	-12.9x	---
United StatesDNLI Denali Therapeutics Inc	3.1B	-22.5x	---
United StatesADMA ADMA Biologics Inc	2.7B	-558.8x	---
United StatesVCYT Veracyte Inc	1.6B	-22.7x	---
As of 2024-07-02

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact Information

Headquarters: Carl Jacobsens Vej 30KOEBENHAVN V, Denmark 2500
Phone: ---
Fax: ---

Executives

Independent Chairman of the Board: Deirdre Connelly
President, Chief Executive Officer: Jan Van De Winkel
Independent Deputy Chairman of the Board: Pernille Erenbjerg
Chief Financial Officer, Executive Vice President: Anthony Pagano
Chief Operating Officer, Executive Vice President: Anthony Mancini

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$16.5B
Revenue (TTM)	$2.6B
Shares Outstanding	661.4M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.97
EPS	$1.19
Book Value	$6.97
P/E Ratio	20.9x
Price/Sales (TTM)	6.4
Price/Cash Flow (TTM)	---
Operating Margin	32.00%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Genmab A/S
NASDAQ:GMABUnited States

Search Criteria

Charts

Recent News

Jun 28, 2024

Epcoritamab (TEPKINLY(R) ) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma, from 2:00AM ET on Friday Jun 28, 2024 by Dow Jones

Epcoritamab (TEPKINLY(R)) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma, from 2:00AM ET on Friday Jun 28, 2024 by Dow Jones

Jun 27, 2024

DJ Genmab Is Maintained at Buy by BTIG, from 8:11AM ET on Thursday Jun 27, 2024 by Dow Jones

DJ Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 6:41AM ET on Thursday Jun 27, 2024 by Dow Jones

Jun 26, 2024

DJ AbbVie Gets New FDA Accelerated Approval for Epkinly, from 7:35PM ET on Wednesday Jun 26, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar